Aerpio Therapeutics, Inc.

Invirsa, Inc.

Abbott Laboratories Corporation

Akebia Therapeutics, Inc.

Eyepoint Pharmaceuticals, Inc.

Glaxosmithkline LLC

Aerpio Pharmaceuticals, Inc.

Keith E. Rushlow

Tapas Das

Anand Seth

Terry B. Mazer

Robert A. Shalwitz

Normanella T. Dewille

Robert A Shalwitz

Kevin Gene Peters

Joseph H Gardner

John M Janusz

Terrence B Mazer

Alexander Smith

Anna Kotsakis Ruehlmann

Joseph E Walton

Ronita K Geckle

Shengde Wu

Normanella Dewille

John J Kropczynski, Jr

Rhonda L Cole

Charlotte Suzanne Hartman

Ralph T Doyle, Jr

Roelof M L Rongen

Keith E Rushlow

Douglas Kling

Terry B Mazer

Akshay Buch

Isaiah Shalwitz

Charlotte Hartman

Normanella T Dewille

Joseph Gardner

John Janusz

The present invention is directed to methods for the use of 5'-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.

Methods for the use of 5'-adenosine diphosphate ribose (ADPR)

The present invention is directed to methods for the use of 5'-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

Compositions, formulations and methods for treating ocular diseases

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

Methods for treating vascular leak syndrome and cancer

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and methods for treating anemia

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.

Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1&#x3b1;), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

Prolyl hydroxylase inhibitors

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

Treatment of ocular disease

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

Compositions and methods for treating ocular diseases

Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.

Compounds, compositions, and methods for preventing metastasis of cancer cells

Growing community of inventors

Columbus, OH, United States of America

Robert A Shalwitz